Tuesday, July 7, 2015

Blue Bell-based Inovio Pharmaceuticals signs deal with Roche

Blue Bell-based start up Inovio Pharmaceuticals signed a partnership deal with Swiss-based drugmaker Roche that pays $10 million up front but could yield as much as $412 million if Inovio's prostate cancer and hepatitis B immunotherapy products pan out.

Blue Bell-based Inovio Pharmaceuticals signs deal with Roche

0 comments
Inovio Pharmeceuticals´ corporate logo.
Inovio Pharmeceuticals' corporate logo.
Travel Deals

Blue Bell-based start up Inovio Pharmaceuticals signed a partnership deal with Swiss-based drugmaker Roche that pays $10 million up front but could yield as much as $412 million if Inovio's prostate cancer and hepatitis B immunotherapy products pan out.

Revenue from the sale of drugs derived from the compounds - an innovative process is also part of the deal - are a long way off. The testing completed has only been on animals.

Roche, which is based in Basel and has operations in New Jersey, will provide research and development support to Inovio. The potentially big payout down the road depends on drugs meeting clinical and then sales milestones.

"This partnership represents an important milestone in Inovio's growth and maturing product portfolio. Roche brings to our immunotherapy candidates its leadership position and track record for developing and marketing innovative first-in-class therapies," Inovio President and Chief Executive Officer J. Joseph Kim said in a statement. "Collaborating with the world's preeminent oncology development partner allows us to rapidly advance two of our promising near-clinical stage immunotherapy products from our product pipeline."

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter